Evusheld is no longer authorized for use to help prevent COVID-19 in the United States “until further notice,” due to a lack of protection against dominant variants, according to new guidance issued by the FDA.
In its updated guidance, the FDA limited the use of Evusheld (tixagevimab plus cilgavimab, AstraZeneca) to when the combined national frequency of variants that are not susceptible to the treatment is 90% or less. Read more in Healio.